Eleusis Therapeutics is a private psychedelics company that is turning a lot of heads with its research on micro-doses of LSD as a treatment for Alzheimer's.
Exploring the companies and themes that make up this emerging and exciting new sector
ATAI launches IntroSpect Digital Therapeutics, Appoints veteran software engineer David Keene as CEO
ATAI is adding a digital therapeutics division to its R&D platform.
Numinus announces Clinical Advisory Council to advance its integrated wellness model
Numinus' new Clinical Advisory Council will provide support for its psychedelic drug R&D at all levels.
Osoyoos Announces Agreement to Acquire AI Pharmaceuticals Jamaica Limited
Osoyoos cannabis has acquired a psilocybin-focuse biopharma company based in Jamaica.
Mydecine Innovations Group Inc. Signs Partnership Agreement With Applied Pharmaceutical Innovation
Mydecine announces research agreement with a leading pharmacology research institution.
North Sur Resources and Mindset Pharma Announce Proposed Transaction to Accelerate Development of Medical Psychedelics Industry
An amalgamation of two private companies as psychedelics company Mindset Pharma Inc prepares to go public.
Mydecine Innovations Inks Important Research Agreement
Mydecine's research agreement with the University of Alberta is a key stepping-stone in expediting its psilocybin-based drug development research.
Mydecine Innovations Group Adds Former Pfizer, Novartis, Yale Drug Discovery Expert to Scientific Advisory Board
Mydecine's new Scientific Advisor will work directly with the CSO in drug development initiatives.
Mira X Acquisition Corp. Announces Proposed Qualifying Transaction with Field Trip Psychedelics Inc
Field Trip Psychedelics is planning to go public via a "three-cornered" RTO.
What Does Field Trip Psychedelics Offer Investors?
Field Trip Psychedelics has just announced a letter of intent to go public via RTO.
New Wave Holdings Appoints Dr. Dennis McKenna to Psychedelic Research Advisory Board
New Wave Holdings Corp has added a recognized expert in psychedelic medicine to the company's Advisory Board.
GreenStar Biosciences Signs Agreement to Acquire 100% of Eleusian Biosciences Corp.
Greenstar Biosciences is entering the psychedelics space via its acquisition of Eleusian Biosciences Corp.